meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
sintilimab based treatment
sintilimab
Immune checkpoint association
nivolumab plus ipilimumab
no study with result for this clinical condition